PCYOX1

Across TCGA pan-cancer cohorts, PCYOX1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCYOX1 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCYOX1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PCYOX1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, SKCM, and PRAD are the cancer types where PCYOX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.627	.014	30	view →
SKCM	DFS	Median	All	0.198	0.728	.015	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BRCA	DFS	Median	All	0.647	0.902	.023	4	view →
LUAD	OS	Median	II,III,IV	1.000	0.209	.029	4	view →
COAD	OS	Median	IV	0.140	0.657	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCYOX1–UCEC (DFS)

Open the UCEC breakdown →